NCT05665114 is a Phase 1 clinical trial of QN-030a in AML, Adult, sponsored by Zhejiang University.

Who is sponsoring NCT05665114?

NCT05665114 is sponsored by Zhejiang University.

What drugs are being tested in NCT05665114?

Interventions in NCT05665114: QN-030a, Cyclophosphamid, Fludarabine, Cytarabine, VP-16.

What condition does NCT05665114 study?

NCT05665114 studies AML, Adult.

Is NCT05665114 still recruiting?

NCT05665114 is currently status unknown. Last updated 3 January 2023.

Last reviewed 2023-01-03 · How we verify

NCT05665114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Natural Killer(NK) Cell Therapy in r/r AML

Status unknown Phase 1 Last updated 3 January 2023

What this trial tests

Phase 1 trial testing QN-030a in AML, Adult in 18 participants. Status unknown.

Timeline

24 December 2022

Primary endpoint
24 December 2023

24 December 2025

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	24 December 2022
Primary completion	24 December 2023
Estimated completion	24 December 2025
Sites	1 location across China

Drugs / interventions tested

QN-030a
Cyclophosphamid — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
Cytarabine — full drug profile →
VP-16 — full drug profile →

Conditions studied

AML, Adult — all drugs for AML, Adult →

Sponsor

Zhejiang University

Who can join

18 and older, any sex, with AML, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in relapse/refractory Acute Myeloid Leukemia (AML). This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-030a in patients with r/r AML, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML.
Kent A, Crump LS, Davila E. · · 2023 · cited 21× · PMID 37654497 · DOI 10.3389/fimmu.2023.1202950
NK cell-based immunotherapy strategies for myeloid leukemia.
Zhang L, Zhao Y, Dong Y, Jiang X. · · 2025 · cited 4× · PMID 40726987 · DOI 10.3389/fimmu.2025.1621885

Verify or expand the search:

Other trials of QN-030a

Trials testing the same drug.

NCT05601830 — Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease · Phase 1 · terminated

Other recruiting trials for AML, Adult

Currently open trials in the same condition.

NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
NCT07132684 — Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients · Phase 3 · recruiting
NCT06533761 — Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML · Phase 1 · recruiting
NCT07117422 — Venetoclax-Decitabine in Untreated Elderly/Unfit AML · NA · recruiting
NCT06313437 — Revumenib in Combination With 7+3 + Midostaurin in AML · Phase 1 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05665114 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 3 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05665114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing